Compare Crispr Therapeutics AG (CRSP) vs Energy Select Sector SPDR Fund (XLE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Energy Select Sector SPDR Fund — how do they compare? Crispr Therapeutics AG trades at $53.3 (market cap $4.88B), while Energy Select Sector SPDR Fund trades at $65.44 (market cap $40.84B). The key difference: Energy Select Sector SPDR Fund is far larger — about 8.4× Crispr Therapeutics AG's market cap, and Energy Select Sector SPDR Fund is trading nearer its 52-week high, Crispr Therapeutics AG nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Crispr Therapeutics AG for 77 Days and Energy Select Sector SPDR Fund for 67 Days on average.
| CRSP | XLE | |
|---|---|---|
Market Cap | $4.88B | $40.84B |
Volume | 2,861,747 | 50,409,268 |
Sector | Health | — |
52-Week High | $74.92 | $65.93 |
52-Week Low | $44.34 | $42.61 |
Typical Hold Time | 77 Days | 67 Days |
Enterprise Value | $3.30B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $52.35, down 3.06% with bearish technical signals. The company shows negative profitability metrics including -$581.6M net income and -4,101.26% net margin for 2025, though revenue is expected to grow from $0 to $11M in 2026. Recent news highlights upcoming clinical data presentations and CASGEVY's commercial potential, with analyst consensus leaning bullish despite fundamental challenges.
The outlook remains speculative with significant cash burn but promising pipeline catalysts. Investment opportunity lies in gene-editing breakthroughs and CASGEVY adoption, while risks include sustained losses, clinical trial outcomes, and competitive pressure. Wall Street maintains a $67.83 price target, suggesting 30% upside if execution improves.
XLE (Energy Select Sector SPDR ETF) trades at $65.46, up 3.28% with strong bullish momentum from moving averages but overbought RSI signals. The ETF faces mixed sentiment as oil prices surge above $100 amid Middle East tensions while futures traders bet on a 12% energy sector decline. Recent news highlights strategic oil reserve concerns and diesel price pressures, creating volatility in energy markets.
Outlook remains volatile with geopolitical risks and Fed policy influencing energy prices. The ETF's 91% oil and gas concentration offers pure energy exposure but amplifies crude price sensitivity. Key risks include oil price reversals and export restrictions, while institutional flows into midstream ETFs suggest defensive positioning within the sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Energy Select Sector SPDR Fund
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes companies that have been identified as energy companies by the GICS®, including securities of companies from the following industries: oil, gas and consumable fuels; and energy equipment and services. It is non-diversified.
Read more on XLE →
